Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion Healthcare Co., Ltd.
  6. News
  7. Summary
    A091990   KR7091990002

CELLTRION HEALTHCARE CO., LTD.

(A091990)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EU signs joint procurement deal for Eli Lilly COVID-19 treatment

09/21/2021 | 02:52pm EST

BRUSSELS, Sept 21 (Reuters) - The European Commission has signed a joint procurement contract with U.S. drugmaker Eli Lilly and Co for the supply of a monoclonal antibody treatment for COVID-19, the EU executive arm said in a statement on Tuesday.

The treatment is under review by the European Medicines Agency, it said, and 18 EU countries have signed up to the joint procurement for the purchase of enough to treat up to 220,000 patients.

The deal is part of a portfolio of five promising therapeutics announced by the Commission under the EU's COVID-19 Therapeutics Strategy in June. It also includes treatments from GlaxoSmithKline Plc and Vir Biotechnology Inc, Regeneron Pharmaceuticals Inc and Celltrion HealthCare Co.

"We need to continue our work to prevent illness with vaccines and at the same time ensure that we can treat it with therapeutics," EU Commissioner for Health Stella Kyriakides said. (Reporting by Jan Strupczewski; Editing by Bill Berkrot)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION HEALTHCARE CO., LTD. 1.43% 85200 End-of-day quote.-47.73%
CELLTRION, INC. 2.39% 214000 End-of-day quote.-40.39%
GLAXOSMITHKLINE PLC -1.90% 1510.8 Delayed Quote.12.58%
REGENERON PHARMACEUTICALS -0.75% 643.35 Delayed Quote.33.17%
VIR BIOTECHNOLOGY, INC. 12.43% 36 Delayed Quote.34.43%
All news about CELLTRION HEALTHCARE CO., LTD.
11/14Celltrion Healthcare Announces Approval of Regkirona from European Commission
CI
11/12EC Formally Authorises COVID-19 Drugs From Regeneron-Roche, Celltrion
RE
11/09Amid spike in cases, EU to shortly approve first COVID antibody drugs - sources
RE
11/09Amid spike in cases, EU to shortly approve first COVID antibody drugs - sources
RE
10/03Celltrion Healthcare Showcases Positive Data on Switching and Monotherapy with Remsima«..
CI
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/20180 LIFE SCIENCES : Plans Supply Deal With Celltrion Healthcare For Anti-TNF Product Trial..
MT
09/18Celltrion Receives Approval from Korean Ministry of Food and Drug Safety for regdanvima..
CI
09/17South Korea approves Celltrion's COVID-19 treatment for use
RE
08/02Celltrion Healthcare Canada Limited Announces Acceptance and Priority Review by Health ..
CI
More news
Financials
Sales 2021 1 704 B 1,43 B 1,43 B
Net income 2021 163 B 0,14 B 0,14 B
Net cash 2021 97,7 B 0,08 B 0,08 B
P/E ratio 2021 80,8x
Yield 2021 -
Capitalization 13 061 B 10 913 M 10 945 M
EV / Sales 2021 7,61x
EV / Sales 2022 5,55x
Nbr of Employees 131
Free-Float 60,7%
Chart CELLTRION HEALTHCARE CO., LTD.
Duration : Period :
Celltrion Healthcare Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION HEALTHCARE CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 85 200,00 KRW
Average target price 109 900,00 KRW
Spread / Average Target 29,0%
EPS Revisions
Managers and Directors
Hyung-Ki Kim Chief Executive Officer & Director
Jung-Jin Seo Chairman
Jung Kim Head-Compliance Support
David Han Independent Director
Eung-Yeol Choe Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION HEALTHCARE CO., LTD.-47.73%10 913
CSL LIMITED10.18%101 196
WUXI BIOLOGICS (CAYMAN) INC.0.58%56 285
SAMSUNG BIOLOGICS CO.,LTD.5.33%48 100
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-0.80%35 680